← Back to the library
SchizophreniaJuly 15, 2023 · 6 min read

Lurasidone: A Review of an Atypical Antipsychotic

A practical look at lurasidone's benefits, trade-offs, and role in schizophrenia and bipolar depression—including what its MDD research does and does not show.

Lurasidone: Benefits and Trade-offs, with unmarked tablets, a neutral blister strip, and indigo-violet sculptural arcs
In this article

Choosing an antipsychotic is not just about whether it can reduce symptoms. It is also about finding a treatment you can live with: one that fits your mood symptoms, physical health, daily routine, and priorities. Lurasidone offers a useful combination of established benefits and a comparatively lighter weight-gain burden than some alternatives—but its own trade-offs deserve equal attention.

What is lurasidone?

Lurasidone, sold as Latuda and in generic forms, is an oral second-generation, or atypical, antipsychotic. In the United States it is approved for schizophrenia in adults and adolescents aged 13–17, and for bipolar I depression as monotherapy in adults and children aged 10–17. Adults may also receive it alongside lithium or valproate for bipolar I depression.17

The word ‘antipsychotic’ describes a medication class, not a judgment about the person taking it. A prescription for bipolar depression does not mean you must be experiencing psychosis.

How does it work?

Lurasidone blocks dopamine D2 and serotonin 5-HT2A receptors. It also blocks 5-HT7 receptors and partially activates 5-HT1A receptors. A blocker reduces receptor activation; a partial agonist activates a receptor less fully than a full agonist. This combination distinguishes its pharmacological profile from simply ‘lowering dopamine everywhere.’8

Laboratory studies found little affinity for histamine H1 or muscarinic receptors. That helps explain interest in its side-effect profile, but receptor findings alone cannot predict an individual's response. The precise contribution of each action to bipolar-depression relief remains incompletely understood.18

Its role in schizophrenia

Lurasidone is an established treatment for schizophrenia, including symptoms assessed in clinical trials such as hallucinations, delusions, and disorganized thinking. The aim is symptom relief that supports daily functioning. It should not be presented as a guaranteed cognitive enhancer or as universally superior to other antipsychotics.1

Lurasidone for bipolar disorder: strongest evidence in bipolar I depression

Bipolar depression is a depressive episode within bipolar disorder, not a separate name for ordinary MDD. Lurasidone's clearest mood-disorder role is the depressed phase of bipolar I. CANMAT/ISBD guidance includes it among first-line options for acute bipolar I depression, with treatment selected around previous response, tolerability, and other clinical needs.4

In a six-week randomized trial, both lurasidone dose groups improved depressive symptoms more than placebo. Average depression-rating improvements were 15.4 points with lurasidone versus 10.7 with placebo. These are group averages—not a promise about an individual—but they show that the benefit goes beyond a theoretical receptor mechanism.2

Treating bipolar disorder also means planning for other phases. Lurasidone's efficacy for acute mania has not been established, and bipolar II use is outside its U.S. indication. A good response during depression is not, by itself, a complete long-term relapse-prevention plan. Discuss the role of other medicines and follow-up rather than assuming one treatment covers every phase.14

What about major depressive disorder (MDD)?

Lurasidone is not FDA-approved for MDD. Its most notable controlled MDD study examined a specific group: people with depression plus two or three protocol-defined manic symptoms below the threshold for a hypomanic episode. That study population should not be treated as interchangeable with all people who have unipolar depression.13

In that six-week trial, 109 participants received lurasidone and 100 received placebo. Depression scores improved by an average of 20.5 versus 13.0 points, respectively. This is an encouraging signal for MDD with mixed features, and a reason a specialist might consider an off-label discussion. It is not broad evidence that lurasidone should routinely replace antidepressants or serve as a standard add-on for MDD without mixed features.3

Mixed features also deserve careful diagnostic review, including previous periods of elevated mood, reduced need for sleep, and increased energy. Some other antipsychotics have different depression indications: for example, aripiprazole is approved as an adjunct to antidepressants for adult MDD. The exact diagnosis and treatment target matter more than the shared medication-class name.36

Potential pros compared with other antipsychotics

Lurasidone may be worth discussing when these priorities matter:

  • A lower average weight-gain burden than olanzapine or quetiapine in short-term bipolar-depression studies. Lower risk does not mean weight gain or metabolic changes cannot happen.5
  • Less sleepiness than quetiapine on average in the same comparative evidence—potentially valuable when daytime alertness is a priority.5
  • Evidence for bipolar-depression relief as well as an established schizophrenia indication, with once-daily oral dosing.12

Potential cons and limitations

A favorable feature in one area does not make a medicine side-effect-free:

  • Akathisia—an uncomfortable inner restlessness or need to keep moving—is an important potential problem. Stiffness, tremor, nausea, and sleepiness can also occur. Do not assume new restlessness is simply your original anxiety.7
  • Each dose needs food, and interactions can make treatment unsuitable or require adjustment.19
  • It is not an established acute-mania treatment or an approved MDD treatment. Those gaps can make a different antipsychotic more appropriate for a particular episode.16

Lurasidone versus other antipsychotics

The comparison below highlights practical trade-offs, not a ranking of ‘best’ drugs. Much of the bipolar-depression comparison evidence comes from short-term network meta-analysis, which combines trials indirectly rather than testing every pair head-to-head. Individual outcomes may differ; some of this research was industry-supported.5

Lurasidone compared with three commonly discussed alternatives
Compared withPotential reason to choose lurasidoneTrade-off or reason to consider the alternative
QuetiapineLurasidone generally has a lower weight-gain and sleepiness burden in short-term bipolar-depression comparisons.5Quetiapine has a broader bipolar-treatment role, including mania and maintenance; it is also a first-line guideline option for bipolar II depression.4
OlanzapineLurasidone generally causes less weight gain in short-term bipolar-depression trials.5Olanzapine has an established role in acute mania. Lurasidone's depression benefit should not be assumed to cover a manic episode.14
AripiprazoleLurasidone has positive acute bipolar-depression evidence; aripiprazole is not recommended as monotherapy for that phase in CANMAT/ISBD guidance.24Aripiprazole has approved roles in bipolar mania and as an add-on to antidepressants for MDD, and no meal requirement. Akathisia can occur with either medicine.16

Taking it: food and interactions matter

Take lurasidone once daily with at least 350 calories of food. Two crossover studies found substantially greater drug exposure with food than while fasting; meal fat content was not the key factor. An existing suitable meal may meet the requirement—you do not necessarily need to add an extra meal to your day.9

Lurasidone is mainly metabolized through CYP3A4. Strong inhibitors or inducers are contraindicated, including certain combinations with clarithromycin, ketoconazole, ritonavir, rifampin, carbamazepine, or St. John's wort. Moderate inhibitors can require dose changes. Avoid grapefruit and have your pharmacist check all medicines and supplements.1

Dose ranges differ between schizophrenia and bipolar depression, and kidney or liver impairment can change dosing. Follow your own prescription; do not copy someone else's dose or switch antipsychotics abruptly.17

Monitoring and symptoms to report

Monitoring still matters even with a comparatively favorable weight profile. Review weight, blood sugar, cholesterol, movement symptoms, and symptoms of increased prolactin such as missed periods, breast discharge, or sexual changes. Tell your clinician about pregnancy, breastfeeding, other medical conditions, and all other treatments.17

Report new involuntary movements or persistent restlessness promptly. Fever with severe stiffness and confusion, seizures, or difficulty breathing or swallowing needs urgent medical assessment. New suicidal thoughts or sharply worsening mood need immediate attention; seek emergency help if you cannot stay safe.7

Like other antipsychotics, lurasidone carries a boxed warning about increased mortality in older adults with dementia-related psychosis and is not approved for that use.7

Questions to bring to your prescriber

Which symptoms and phase of illness are we targeting? What improvement should I look for, and when will we review it? How will we handle akathisia or nausea? Can my routine reliably accommodate the food requirement? What monitoring and longer-term plan do I need?

These questions turn a medication choice into a shared plan. Needing a different option after an unsuccessful trial is not a personal failure.

The takeaway

Lurasidone is a meaningful option for schizophrenia and bipolar I depression, especially when balancing symptom relief with concerns about weight gain or daytime sedation. MDD with mixed features is a promising but distinct off-label conversation. The best choice is the one whose benefits, side effects, and treatment role fit your life—not the one that wins every category on paper.

Words worth knowing

Cognitive behavioral therapy (CBT)

A structured therapy that helps people notice patterns between thoughts, feelings, and actions, then practice more helpful responses.

References

  1. Latuda (lurasidone) U.S. prescribing information. Revised January 2025: indications, dosing, warnings, interactions, and pharmacology.
  2. Loebel A, et al. Lurasidone monotherapy in bipolar I depression: a randomized, double-blind, placebo-controlled study. American Journal of Psychiatry. 2014;171:160–168.
  3. Suppes T, et al. Lurasidone for major depressive disorder with mixed features: a randomized, double-blind, placebo-controlled study. American Journal of Psychiatry. 2016;173:400–407.
  4. Keramatian K, et al. CANMAT and ISBD guidelines for bipolar disorder: summary and a 2023 update of evidence. Focus. 2023.
  5. Kadakia A, et al. Efficacy and tolerability of atypical antipsychotics for acute bipolar depression: a network meta-analysis. BMC Psychiatry. 2021;21:249.
  6. DailyMed. Abilify (aripiprazole) prescribing information: indications, meal instructions, and adverse effects.
  7. MedlinePlus. Lurasidone: patient precautions, side effects, and safety warnings.
  8. Ishibashi T, et al. Pharmacological profile of lurasidone. Journal of Pharmacology and Experimental Therapeutics. 2010;334:171–181. Laboratory receptor and animal research.
  9. Preskorn S, et al. Effect of food on lurasidone pharmacokinetics: two randomized crossover studies. Human Psychopharmacology. 2013;28:495–505.
Educational content—not medical advice.Find support resources →